The price of Cytek Biosciences Inc. (NASDAQ: CTKB) closed at $6.69 in the last session, down -4.43% from day before closing price of $7.00. In other words, the price has decreased by -$0.31 from its previous closing price. On the day, 543240 shares were traded. CTKB stock price reached its highest trading level at $6.98 during the session, while it also had its lowest trading level at $6.69.
We take a closer look at CTKB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.70 and its Current Ratio is at 7.90. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 07 when Jiang Wenbin sold 20,000 shares for $6.83 per share. The transaction valued at 136,600 led to the insider holds 7,605,796 shares of the business.
Jeanmonod Patrik sold 3,000 shares of CTKB for $23,070 on Aug 24. The Chief Financial Officer now owns 102,084 shares after completing the transaction at $7.69 per share. On Aug 21, another insider, Yan Ming, who serves as the Chief Technology Officer of the company, sold 20,000 shares for $8.07 each. As a result, the insider received 161,400 and left with 7,815,962 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTKB now has a Market Capitalization of 912.25M and an Enterprise Value of 629.62M. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.24 while its Price-to-Book (P/B) ratio in mrq is 2.14. Its current Enterprise Value per Revenue stands at 3.59 whereas that against EBITDA is -1.69k.
Stock Price History:
Over the past 52 weeks, CTKB has reached a high of $15.90, while it has fallen to a 52-week low of $6.45. The 50-Day Moving Average of the stock is 8.32, while the 200-Day Moving Average is calculated to be 9.59.
According to the various share statistics, CTKB traded on average about 877.03K shares per day over the past 3-months and 1.42M shares per day over the past 10 days. A total of 135.92M shares are outstanding, with a floating share count of 120.69M. Insiders hold about 11.80% of the company’s shares, while institutions hold 53.10% stake in the company. Shares short for CTKB as of Aug 30, 2023 were 11.82M with a Short Ratio of 11.82M, compared to 12.02M on Jul 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 8.67% and a Short% of Float of 9.80%.
The company has 4 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.02 for the current quarter, with a high estimate of $0.04 and a low estimate of $0.01, while EPS last year was $0.04. The consensus estimate for the next quarter is $0.06, with high estimates of $0.08 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.21 and $0.06 for the fiscal current year, implying an average EPS of $0.12. EPS for the following year is $0.22, with 4 analysts recommending between $0.25 and $0.2.
According to 4 analysts, the current quarter’s revenue is expected to be $57.64M. It ranges from a high estimate of $61.7M to a low estimate of $53.17M. As of the current estimate, Cytek Biosciences Inc.’s year-ago sales were $43.29M, an estimated increase of 33.10% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $65.22M, an increase of 34.90% over than the figure of $33.10% in the same quarter last year. There is a high estimate of $68.2M for the next quarter, whereas the lowest estimate is $60.44M.
A total of 5 analysts have provided revenue estimates for CTKB’s current fiscal year. The highest revenue estimate was $214M, while the lowest revenue estimate was $200.4M, resulting in an average revenue estimate of $209.66M. In the same quarter a year ago, actual revenue was $164.04M, up 27.80% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $276.3M in the next fiscal year. The high estimate is $289.2M and the low estimate is $252.29M. The average revenue growth estimate for next year is up 31.80% from the average revenue estimate for this year.